CL2018001573A1 - Compuestos de isoindol - Google Patents
Compuestos de isoindolInfo
- Publication number
- CL2018001573A1 CL2018001573A1 CL2018001573A CL2018001573A CL2018001573A1 CL 2018001573 A1 CL2018001573 A1 CL 2018001573A1 CL 2018001573 A CL2018001573 A CL 2018001573A CL 2018001573 A CL2018001573 A CL 2018001573A CL 2018001573 A1 CL2018001573 A1 CL 2018001573A1
- Authority
- CL
- Chile
- Prior art keywords
- rent
- alcoxi
- replaced
- cyclopropyl
- halo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
UN COMPUESTO DE FÓRMULA (I), DONDE R 1 ES H O (CO)R4; R 2 ES ALQUILO C1-6, CICLOPROPILO, CH2-CICLOPROPILO, O NR5R 6, EN LA QUE DICHO ALQUILO C1-6 ESTÁ OPCIONALMENTE SUSTITUIDO CON OH O ALCOXI C1-6 Y DICHO CH2-CICLOPROPILO ESTÁ OPCIONALMENTE SUSTITUIDO CON HALO, OH, CN O ALCOXI C1-6; R 3 ES H, ALQUILO C1-6, ALCOXI C1-6, HALO O CN. R 4 ES: - H; - ALQUILO C1-6 OPCIONALMENTE SUSTITUIDO CON (R7)A; - CICLOALQUILO C3-7 OPCIONALMENTE SUSTITUIDO CON HALO, ALQUILO C1-6, OH, CN, ALCOXI C1-6, O ALQUILO C1-3-OR8; - HETEROCICLOALQUILO OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-6 U OH; - ALCOXI C1-6; O - NHR13; A ES 1, 2 O 3; R 6 ES H, ALQUILO C1-6 O CICLOALQUILO C3-7; 278 R 7 SE SELECCIONA INDEPENDIENTEMENTE DEL GRUPO QUE CONSISTE EN HALO, OH, CN, ALCOXI C1-6, NR9R 10, CICLOALQUILO C3-7, HETEROCICLOALQUILO Y ARILO, EN LA QUE DICHOS GRUPOS CICLOALQUILO C3- 7, HETEROCICLOALQUILO O ARILO ADICIONALMENTE ESTÁN OPCIONALMENTE SUSTITUIDOS CON 1, 2 O 3 GRUPOS SELECCIONADOS INDEPENDIENTEMENTE DEL GRUPO QUE CONSISTE EN ALQUILO C1-6, CN, OH, ALCOXI C1-6 Y NR11R 12; R 13 ES H, ALQUILO C1-6 O CICLOALQUILO C3-7; CADA UNO DE R5, R8, R9, R10, R11 Y R12 ES INDEPENDIENTEMENTE H O ALQUILO C1-6; O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267391P | 2015-12-15 | 2015-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018001573A1 true CL2018001573A1 (es) | 2018-07-27 |
Family
ID=57708552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018001573A CL2018001573A1 (es) | 2015-12-15 | 2018-06-13 | Compuestos de isoindol |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10011566B2 (es) |
| EP (1) | EP3390396B1 (es) |
| JP (1) | JP6448867B2 (es) |
| KR (1) | KR101947976B1 (es) |
| CN (1) | CN109071516B (es) |
| AR (1) | AR107054A1 (es) |
| AU (1) | AU2016374294B2 (es) |
| BR (1) | BR112018011851A2 (es) |
| CA (1) | CA3007893A1 (es) |
| CL (1) | CL2018001573A1 (es) |
| CO (1) | CO2018005983A2 (es) |
| CR (1) | CR20180328A (es) |
| DO (1) | DOP2018000148A (es) |
| EA (1) | EA034514B1 (es) |
| ES (1) | ES2927631T3 (es) |
| IL (1) | IL259818B (es) |
| MX (1) | MX2018007296A (es) |
| MY (1) | MY196276A (es) |
| NI (1) | NI201800071A (es) |
| PE (1) | PE20181319A1 (es) |
| PH (1) | PH12018501237A1 (es) |
| SG (1) | SG11201804587QA (es) |
| SV (1) | SV2018005713A (es) |
| TN (1) | TN2018000188A1 (es) |
| TW (1) | TWI728017B (es) |
| WO (1) | WO2017102784A1 (es) |
| ZA (1) | ZA201804618B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY196276A (en) | 2015-12-15 | 2023-03-24 | Astrazeneca Ab | Isoindole Compounds |
| CN110730780A (zh) * | 2017-06-14 | 2020-01-24 | 阿斯利康(瑞典)有限公司 | 用作ROR-γ调节剂的2，3-二氢异吲哚-1-甲酰胺 |
| WO2020035557A1 (en) | 2018-08-17 | 2020-02-20 | Leo Pharma A/S | Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma |
| WO2020035556A1 (en) | 2018-08-17 | 2020-02-20 | Leo Pharma A/S | Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma |
| TW202208338A (zh) * | 2020-05-15 | 2022-03-01 | 大陸商上海輝启生物醫藥科技有限公司 | 可用作RORγ調節劑的苯胺類化合物 |
| CN113666863B (zh) * | 2020-05-15 | 2024-06-11 | 励缔(杭州)医药科技有限公司 | 可用作RORγ调节剂的联芳基类化合物 |
| KR102422891B1 (ko) | 2022-01-26 | 2022-07-20 | (주)셀시스템 | Ai기반 우선순위 제어기능을 구비한 일체형 태양광 온수 및 배터리 충전장치 및 이를 이용한 충전 방법 |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9414139D0 (en) | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Novel compounds |
| US6066738A (en) | 1996-01-30 | 2000-05-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CN1298404A (zh) | 1998-02-25 | 2001-06-06 | 遗传研究所有限公司 | 磷脂酶a2的抑制剂 |
| US6316503B1 (en) | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
| WO2001003705A1 (en) | 1999-07-08 | 2001-01-18 | Tularik Inc. | Compositions and methods for raising hdl cholesterol levels |
| AU5959201A (en) | 2000-05-11 | 2001-11-20 | Bristol Myers Squibb Co | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| AU2001288623A1 (en) | 2000-09-05 | 2002-03-22 | Tularik, Inc. | Fxr modulators |
| JP2004515494A (ja) | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | 治療剤 |
| AU2002236830A1 (en) | 2001-01-26 | 2002-08-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors |
| US6649606B1 (en) | 2001-11-09 | 2003-11-18 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| WO2003082198A2 (en) | 2002-03-27 | 2003-10-09 | Smithkline Beecham Corporation | Methods of treatment with lxr modulators |
| AU2003227689A1 (en) | 2002-04-29 | 2003-11-17 | Novartis Ag | Crystal structure of the ligand binding domain of the retinoic acid-related orphan receptor alpha (ror-alpha) |
| EP1646394A2 (en) | 2003-07-22 | 2006-04-19 | Glaxo Group Limited | Methods of treatment with lxr agonists |
| EP1653938A2 (en) | 2003-07-28 | 2006-05-10 | Glaxo Group Limited | Methods of treatment of inflammatory bowel disease with lxr agonists |
| WO2005055998A1 (en) | 2003-12-04 | 2005-06-23 | Smithkline Beecham Corporation | Methods of treatment with lxr agonists |
| WO2006091862A2 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Cytokine inhibitors and their use in therapy |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| WO2007055374A1 (ja) | 2005-11-14 | 2007-05-18 | Mitsubishi Tanabe Pharma Corporation | 骨粗鬆症治療剤 |
| UY30118A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compueto amina trisustituido |
| TW200808723A (en) | 2006-03-13 | 2008-02-16 | Univ California | Conformationally restricted urea inhibitors of soluble epoxide hydrolase |
| WO2007146712A2 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| TW200812962A (en) | 2006-07-12 | 2008-03-16 | Astrazeneca Ab | New compounds I/418 |
| JP2009542803A (ja) * | 2006-07-12 | 2009-12-03 | アストラゼネカ・アクチエボラーグ | 鎮痛剤としての３−オキソイソインドリン−１−カルボキサミド誘導体 |
| WO2008033567A1 (en) | 2006-09-15 | 2008-03-20 | Celgene Corporation | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
| JP4834699B2 (ja) | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP4846769B2 (ja) | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2011115892A1 (en) * | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
| WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012028100A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012100732A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof |
| WO2012100734A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
| EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
| US9586928B2 (en) | 2011-05-16 | 2017-03-07 | The Scripps Research Institute | Modulators of the nuclear hormone receptor ROR |
| WO2013029338A1 (en) | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
| WO2013100027A1 (ja) | 2011-12-28 | 2013-07-04 | 武田薬品工業株式会社 | 複素環化合物 |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9321750B2 (en) | 2012-04-20 | 2016-04-26 | Innov17 Llc | ROR modulators and their uses |
| WO2013166015A1 (en) | 2012-04-30 | 2013-11-07 | Anderson Gaweco | Ror modulators and their uses |
| WO2013166013A1 (en) | 2012-04-30 | 2013-11-07 | Anderson Gaweco | Ror modulators and their uses |
| KR101936851B1 (ko) * | 2012-07-16 | 2019-01-11 | 한국과학기술연구원 | 단백질 키나아제 저해제인 신규 피라졸로피리딘 유도체 또는 인다졸 유도체 |
| WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
| WO2014125426A1 (en) | 2013-02-15 | 2014-08-21 | Aurigene Discovery Technologies Limited | Trisubstituted heterocyclic derivatives as ror gamma modulators |
| WO2014165816A1 (en) | 2013-04-05 | 2014-10-09 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
| WO2014179564A1 (en) | 2013-05-01 | 2014-11-06 | Vitae Pharmaceuticals, Inc. | Thiazalopyrrolidine inhibitors of ror-gamma |
| WO2015002231A1 (ja) | 2013-07-03 | 2015-01-08 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6411342B2 (ja) | 2013-07-03 | 2018-10-24 | 武田薬品工業株式会社 | アミド化合物 |
| WO2015017335A1 (en) | 2013-07-30 | 2015-02-05 | Boehringer Ingelheim International Gmbh | Azaindole compounds as modulators of rorc |
| EP3041821B1 (en) | 2013-09-05 | 2018-05-30 | Boehringer Ingelheim International GmbH | Bicylic compounds as modulators of rorgamma |
| LT3077372T (lt) | 2013-12-05 | 2019-03-25 | Lead Pharma Holding B.V. | Ror gama (rory) moduliatoriai |
| WO2015083130A1 (en) | 2013-12-06 | 2015-06-11 | Aurigene Discovery Technologies Limited | Fused pyridine and pyrimidine derivatives as ror gamma modulators |
| WO2015101928A1 (en) | 2013-12-31 | 2015-07-09 | Aurigene Discovery Technologies Limited | Fused thiophene and thiazole derivatives as ror gamma modulators |
| US9266886B2 (en) | 2014-02-03 | 2016-02-23 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2015129853A1 (ja) | 2014-02-27 | 2015-09-03 | 東レ株式会社 | 環状アミン誘導体及びその医薬用途 |
| CA2942871A1 (en) | 2014-03-27 | 2015-10-01 | Piramal Enterprises Limited | Ror-gamma modulators and uses thereof |
| CN107266454B (zh) | 2014-04-14 | 2019-08-09 | 勃林格殷格翰国际有限公司 | 作为RORγ调节剂的化合物 |
| SG11201607518RA (en) | 2014-04-16 | 2016-10-28 | Glenmark Pharmaceuticals Sa | Aryl and heteroaryl ether compounds as ror gamma modulators |
| US9365520B2 (en) | 2014-07-01 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| NZ729137A (en) | 2014-08-04 | 2022-07-29 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| MA40759A (fr) | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
| SG11201702362SA (en) | 2014-10-14 | 2017-04-27 | Vitae Pharmaceuticals Inc | Dihydropyrrolopyridine inhibitors of ror-gamma |
| JP2017538676A (ja) | 2014-11-05 | 2017-12-28 | ザ ユニバーシティ オブ カンザス | ミトコンドリア透過性遷移孔（ｍｔＰＴＰ）の小分子阻害剤 |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| WO2016176399A1 (en) | 2015-04-28 | 2016-11-03 | Stc.Unm | Compositions and methods for treatment of pulmonary hypertension |
| HUE054009T2 (hu) | 2015-05-15 | 2021-08-30 | Aurigene Discovery Tech Ltd | Szubsztituált tetrahidrokinolinon vegyületek ROR gamma modulátorként |
| EP3101007A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| EP3101008A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| EP3101009A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| EP3101006A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| EP3101005A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| WO2017010399A1 (ja) | 2015-07-10 | 2017-01-19 | 塩野義製薬株式会社 | ＲＯＲγｔ阻害作用を有する化合物およびそれらを含有する医薬組成物 |
| DK3331876T3 (da) | 2015-08-05 | 2021-01-11 | Vitae Pharmaceuticals Llc | Modulators of ror-gamma |
| EP3356366B1 (en) | 2015-10-01 | 2019-08-28 | Boehringer Ingelheim International GmbH | Pteridine derivatives as modulators of ror gamma |
| MY196276A (en) | 2015-12-15 | 2023-03-24 | Astrazeneca Ab | Isoindole Compounds |
-
2016
- 2016-12-14 MY MYPI2018702277A patent/MY196276A/en unknown
- 2016-12-14 EA EA201891342A patent/EA034514B1/ru not_active IP Right Cessation
- 2016-12-14 CA CA3007893A patent/CA3007893A1/en active Pending
- 2016-12-14 WO PCT/EP2016/080885 patent/WO2017102784A1/en active Application Filing
- 2016-12-14 TN TNP/2018/000188A patent/TN2018000188A1/en unknown
- 2016-12-14 BR BR112018011851-6A patent/BR112018011851A2/pt not_active Application Discontinuation
- 2016-12-14 US US15/378,360 patent/US10011566B2/en active Active
- 2016-12-14 MX MX2018007296A patent/MX2018007296A/es active IP Right Grant
- 2016-12-14 TW TW105141323A patent/TWI728017B/zh active
- 2016-12-14 CN CN201680072754.5A patent/CN109071516B/zh active Active
- 2016-12-14 JP JP2018530875A patent/JP6448867B2/ja active Active
- 2016-12-14 AU AU2016374294A patent/AU2016374294B2/en not_active Ceased
- 2016-12-14 EP EP16820199.4A patent/EP3390396B1/en active Active
- 2016-12-14 KR KR1020187019921A patent/KR101947976B1/ko active IP Right Grant
- 2016-12-14 ES ES16820199T patent/ES2927631T3/es active Active
- 2016-12-14 PE PE2018001126A patent/PE20181319A1/es unknown
- 2016-12-14 CR CR20180328A patent/CR20180328A/es unknown
- 2016-12-14 SG SG11201804587QA patent/SG11201804587QA/en unknown
- 2016-12-15 AR ARP160103860A patent/AR107054A1/es unknown
-
2018
- 2018-06-04 US US15/997,310 patent/US10526286B2/en active Active
- 2018-06-05 IL IL259818A patent/IL259818B/en active IP Right Grant
- 2018-06-08 PH PH12018501237A patent/PH12018501237A1/en unknown
- 2018-06-13 NI NI201800071A patent/NI201800071A/es unknown
- 2018-06-13 CL CL2018001573A patent/CL2018001573A1/es unknown
- 2018-06-13 CO CONC2018/0005983A patent/CO2018005983A2/es unknown
- 2018-06-14 DO DO2018000148A patent/DOP2018000148A/es unknown
- 2018-06-15 SV SV2018005713A patent/SV2018005713A/es unknown
- 2018-07-11 ZA ZA2018/04618A patent/ZA201804618B/en unknown
-
2019
- 2019-11-25 US US16/693,866 patent/US10988445B2/en active Active
-
2021
- 2021-03-26 US US17/213,326 patent/US11453644B1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001573A1 (es) | Compuestos de isoindol | |
| CO2020004202A2 (es) | Compuestos químicos | |
| CL2017002452A1 (es) | Nuevos compuestos bicíclicos | |
| ZA201906832B (en) | Novel psma-binding agents and uses thereof | |
| EA201791208A1 (ru) | Антитела к cd38 для лечения острого миелолейкоза | |
| MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| BR112017009194A2 (pt) | tetra-hidropiranos substituídos e método de uso | |
| EA201990521A1 (ru) | Усовершенствованное оборудование для отверждения и способы его использования | |
| MX2020001832A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre. | |
| EA201790779A1 (ru) | Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| GB2569754A (en) | Synthesis of AEI and Cu-AEI zeolites | |
| MY186368A (en) | Colony stimulating factor-1 receptor (csf-1r) inhibitors | |
| MY194603A (en) | Anti-Complement Factor Bb Antibodies And Uses Thereof | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| EA201692358A1 (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
| SV2018005700A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| EA201790156A1 (ru) | Азетидинилоксифенилпирролидиновые соединения | |
| EA201791113A1 (ru) | Фармацевтические составы в виде гранул, содержащие диметилфумарат | |
| EA201892235A1 (ru) | Гранулированная композиция для перорального применения | |
| BR112017020374A2 (pt) | compostos bicíclicos fundidos para o tratamento de doença | |
| MX2019003755A (es) | Regimen de dosificacion de avelumab para el tratamiento de cancer. | |
| PH12019500479A1 (en) | Compositions for treating dementia | |
| BR112018074231A2 (pt) | compostos bicíclicos fundidos para o tratamento de doença |